Investors

2019 News

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
Feb 11, 2019CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®
SEATTLE, Feb. 11, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of sales milestones for TRISENOX® (arsenic trioxide). TRISENOX was acquired from CTI BioPharma by Cephalon, Inc. (Cephalon). Cephalon was subsequently acquired by Teva. The milestone was paid pursuant to an acquisition agreement for TRISENOX entered into with Cephalon under which CTI BioPh... 
Printer Friendly Version
Feb 01, 2019CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
- Company announces continuation of PAC203 study following third interim review - SEATTLE, Feb. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that the Company will withdraw its European Marketing Authorization Application (MAA) for pacritinib as a treatment for myelofibrosis. The decision follows recent interactions with the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), during which the Company learned that the committee ... 
Printer Friendly Version